Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6(OASIS-6) trial

American Heart Journal

Volumn 160, Issue 6, 2010, Pages 1049-1055

  Van Rees Vellinga, Tjeerd E ^a   Peters, Ron J G ^a   Yusuf, Salim ^b,c   Afzal, Rizwan ^c   Chrolavicius, Susan ^c   O'Donnell, Martin ^b,c   Mehta, Shamir R ^b,c   Pluta, Wadysław ^d   Sacha, Jerzy ^d   Eikelboom, John W ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d Regional Medical Center in Opole   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GROUPS BY AGE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FACTOR X; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYSACCHARIDES; SYNDROME; TREATMENT OUTCOME;

EID: 78650083646     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.08.038     Document Type: Article

References (11)

1. WHO mortality database 2009 World Health Organization Geneva, Switzerland
2. Sinnaeve P.R., Huang Y., and Bogaerts K. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS Am Heart J 152 2006 684.e1 684.e9
3. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction Lancet 358 2001 605 613
4. White H.D., Braunwald E., and Murphy S.A. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 Eur Heart J 28 2007 1066 1071
5. Yusuf S., Mehta S.R., and Chrolavicius S. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
6. Yusuf S., Mehta S.R., and Xie C. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation JAMA 293 2005 427 435
7. Cannon C.P., Battler A., and Brindis R.G. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee) J Am Coll Cardiol 38 2001 2114 2130
8. Yusuf S., Mehta S.R., and Chrolavicius S. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
9. Antman E.M., Morrow D.A., and McCabe C.H. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) Am Heart J 149 2005 217 2126
10. Anderson J.A., Hirsh J., and Yusuf S. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the OASIS-5 trial JThromb Haemost 8 2010 243 249
11. Yusuf S., Wittes J., and Probstfield J. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials Jama 266 1991 93 98